H.C. Wainwright analyst Douglas Tsao maintained a Buy rating on GW Pharma (NASDAQ:GWPH) on Wednesday, setting a price target of $161, which is approximately 27.24% above the present share price of $126.53.
Tsao expects GW Pharma to post earnings per share (EPS) of $0.00 for the third quarter of 2020.
The current consensus among 7 TipRanks analysts is for a Strong Buy rating of shares in GW Pharma, with an average price target of $182.67.
The analysts price targets range from a high of $275 to a low of $150.
In its latest earnings report, released on 03/31/2020, the company reported a quarterly revenue of $120.63 million and a net profit of -$7.19 million. The company's market cap is $4.03 billion.
According to TipRanks.com, H.C. Wainwright analyst Douglas Tsao is currently ranked with 4 stars on a 0-5 stars ranking scale, with an average return of 8.7% and a 52.36% success rate.
GW Pharmaceuticals (OTC:GWPRF) Plc is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel therapeutics. It offers its cannabinoid product, Epidiolex oral solution CV, a pharmaceutical formulation of cannabidiol (CBD) focusing on the treatment of seizures associated with tuberous sclerosis complex. The company was founded by Geoffrey William Guy and Brian Whittle in 1998 and is headquartered in Cambridge, the United Kingdom.